In August CTS begins source plasma testing as a new line of business to one of the largest plasma fractionators in the industry.
In 2016, CTS tested more source plasma samples (4.9 million) than blood donor samples (4.5 million).
CTS Tampa lab implemented the Ortho Clinical Diagnostics VITROS® testing platform to perform COVID-1...
In July, the six viral marker assay conversion at CTS Dallas, Phoenix and Tampa laboratories was ach...
By the end of 2017, CTS has secured three source plasma partners and continues to seek additional pa...
In August, the CTS Tampa lab transitioned to the same laboratory information systems (LIS) as the Da...
Transitioned all 6 CTS labs from an investigational new drug (IND) to a licensed Zika test, and anno...